GSK Continues R&D Externalization With Option To License Kinase Inhibitors
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at 1http://invivoblog.blogspot.com/.You may also be interested in...
Ahead of ASCO, Exelixis Inks Lucrative Deal With Sanofi For Its PI3 Kinase Inhibitors
GSK’s New Oncology R&D Structure Reflects Personalized Medicine Emphasis
GSK’s New Oncology R&D Structure Reflects Personalized Medicine Emphasis
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: